Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study
Key Finding
Curcumin (1000mg daily) significantly reduced depressive symptoms from week 4, particularly in atypical depression.
Plain-English Summary
This randomized, double-blind, placebo-controlled study examined curcumin for major depression in 56 adults over 8 weeks. Participants received 500mg of curcumin (BCM-95) twice daily or placebo.
From week 4, curcumin was significantly more effective than placebo in reducing depressive symptoms. Greater improvements were observed in atypical depression. Curcumin also reduced inflammatory biomarkers associated with depression.
Curcumin has powerful anti-inflammatory and antioxidant properties. Neuroinflammation is increasingly recognized as a contributing factor in depression. By reducing brain inflammation and modulating neurotransmitter systems, curcumin may address underlying mechanisms of mood disorders. The BCM-95 formulation used has enhanced bioavailability compared to standard curcumin.